Biopeutics

Novel-application reformulations of established molecules

Privately held: no public share price · Taiwan

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
Prostaglandin E1 receptorSmall molecule
Heart FailureAtherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
November 2029 (1)
alprostadilPhase 3End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV
Est. primary completion 2029-11 · NCT00610051 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.